Advancing Research on Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Scientometric Analysis.

Institute Of Climate Adaptation And Marine Biotechnology, Universiti Malaysia Terengganu, Terengganu, Malaysia ,Abdul Matin,Gul-E-Saba Chaudhry,Institute Of Climate Adaptation And Marine Biotechnology, Universiti Malaysia Terengganu, Terengganu, Malaysia ,Mohamad Nor Azra,Institute Of Climate Adaptation And Marine Biotechnology, Universiti Malaysia Terengganu, Terengganu, Malaysia ,Mohamad Gazali,Institute Of Climate Adaptation And Marine Biotechnology, Universiti Malaysia Terengganu, Terengganu, Malaysia ,Yeong Yik Sung,Institute Of Climate Adaptation And Marine Biotechnology, Universiti Malaysia Terengganu, Terengganu, Malaysia ,Tengku Sifzizul Tengku Muhammad,Institute Of Climate Adaptation And Marine Biotechnology, Universiti Malaysia Terengganu, Terengganu, Malaysia

doi:10.21315/mjms2024.31.4.2

Institute Of Climate Adaptation And Marine Biotechnology, Universiti Malaysia Terengganu, Terengganu, Malaysia , Abdul Matin + Show 10 more

Open Access

https://doi.org/10.21315/mjms2024.31.4.2

Copy DOI

Abstract

Atherosclerosis is characterised by the accumulation of fatty deposits and plaque as a result of a continuously high level of low-density lipoprotein cholesterol (LDL-C) in the blood. The primary objective of this research is to assess the current status of knowledge, research endeavours and developmental trajectories about proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in correlation with atherosclerosis treatment. Additionally, this study aims to compile bibliometric and scientometric investigations within this domain through rigorous scientometric analysis. Analysing the bibliometric landscape and global research trends associated with PCSK9 inhibitors can contribute valuable insights into comprehending atherosclerosis. This is exemplified by examining publications within the Web of Science Core Collection (WOSCC) database from 2008 to 2022. Citespace was used for frequency, co-occurrence, co-citation, grouping and burst analysis, and Microsoft Excel was used to manage descriptive datasets. Eight hundred eighty-five publications available from WOSCC database between the years 2008 and 2022 were extracted and examined. Over the period, 3,138 collaborating institutions from 87 countries, a staggering 7,750 writers involved and 325 distinct journals published about PCSK9 inhibitors studies. Among authors, Sabatine et al. and the journal The New England Journal of Medicine has had the most significant impact. Lipid-lowering therapy and bempedoic acid are the most prominent topical clusters associated with PCSK9 inhibitors, and the most often used keywords are efficacy, safety and PCSK9 inhibitors. We believe this is the first comprehensive analysis of PCSK9 inhibitors research and publications conducted using Scientometric. These results demonstrate the nascence of PCSK9 inhibitors research. They may encourage a wide range of stakeholders, particularly early career researchers from various disciplines, to work together in the future.

Full Text